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Abstract
Vascular smooth muscle cells (VSMCs) are the main structural cell of blood vessels, and VSMC apoptosis occurs in vascular 
disease, after injury, and in vessel remodeling during development. Although VSMC apoptosis is viewed as silent, recent 
studies show that apoptotic cells can promote apoptosis-induced compensatory proliferation (AICP), apoptosis-induced 
apoptosis (AIA), and migration of both local somatic and infiltrating inflammatory cells. However, the effects of VSMC 
apoptosis on adjacent VSMCs, and their underlying signaling and mechanisms are unknown. We examined the consequences 
of VSMC apoptosis after activating extrinsic and intrinsic death pathways. VSMCs undergoing apoptosis through Fas/CD95 
or the protein kinase inhibitor staurosporine transcriptionally activated interleukin 6 (IL-6) and granulocyte-macrophage 
colony stimulating factor (GM-CSF), leading to their secretion. Apoptosis induced activation of p38MAPK, JNK, and Akt, 
but neither p38 and JNK activation nor IL-6 or GM-CSF induction required caspase cleavage. IL-6 induction depended upon 
p38 activity, while Fas-induced GM-CSF expression required p38 and JNK. Conditioned media from apoptotic VSMCs 
induced VSMC apoptosis in vitro, and IL-6 and GM-CSF acted as pro-survival factors for AIA. VSMC apoptosis was studied 
in vivo using SM22α-DTR mice that express the diphtheria toxin receptor in VSMCs only. DT administration induced VSMC 
apoptosis and VSMC proliferation, and also signficantly induced IL-6 and GM-CSF. We conclude that VSMC apoptosis 
activates multiple caspase-independent intracellular signaling cascades, leading to release of soluble cytokines involved in 
regulation of both cell proliferation and apoptosis. VSMC AICP may ameliorate while AIA may amplify the effects of pro-
apoptotic stimuli in vessel remodeling and disease.
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Introduction
Vascular smooth muscle cells (VSMCs) are the main struc-
tural cell of blood vessels, and damage or death of VSMCs 
contributes to multiple vascular pathologies. In particular, 
apoptosis of VSMCs has been described in atherosclerosis 
(which underlies most heart attacks and strokes), arterial 
aneurysm, after injury (e.g. percutaneous coronary inter-
vention) and in development. Although chronic apoptosis 
can reduce VSMC number [1], in many cases VSMC apop-
tosis is accompanied by changes in cell proliferation, cell 
migration, inflammation or further apoptosis, for example 
in developmental closure of the ductus arteriosus [2], vessel 
remodeling after changes in blood flow [3–5], vein graft-
ing to arteries [6], and after injury [7]. However, in most 
cases the intracellular pathways triggered by either extrinsic 
(e.g. death receptor) or intrinsic apoptosis pathways, or their 
downstream consequences are not known.
VSMC proliferation after injury has been ascribed to 
exposure to mitogens released from the circulation (e.g. 
Platelet-derived growth factor from platelets) or vessel 
wall (e.g. Fibroblast growth factor). In contrast, VSMCs in 
development or after birth appear to proliferate and remodel 
the artery after apoptosis without exposure to these injury-
induced cytokines. Similarly, VSMC apoptosis after injury is 
extensive, and has been ascribed to the injury stimulus; how-
ever, it’s not clear if the dead cells signal to induce apoptosis 
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of adjacent cells. Although the conventional view is that 
VSMC apoptosis is silent, recent studies have suggested 
that apoptotic cells secrete cytokines or membrane-bound 
ligands; such paracrine effects can promote proliferation 
(apoptosis-induced (compensatory) proliferation, AICP)
[8], apoptosis-induced apoptosis (AIA)[9], or inflammation, 
ameliorating or amplifying the effects of small numbers of 
dead cells in tissues. Furthermore, fundamental parts of the 
apoptosis machinery including caspase enzymes have both 
apoptotic and mitogenic roles simultaneously, coupling 
cell loss with proliferation of adjacent cells (reviewed in 
[10,11]). Remarkably, cells can also tolerate a certain thresh-
old activation of apoptosis without compromising their via-
bility, such that the same cell can be instructed to divide 
(autonomous proliferation), for example by caspase cleavage 
of an inhibitor of proliferation such as p21 [12].
We have examined the signaling pathways and conse-
quences of VSMC apoptosis induced by both extrinsic and 
intrinsic apoptosis pathways in vitro, and VSMC apoptosis 
in vivo. VSMC apoptosis is associated with activation of a 
cascade of intracellular proteins and secretion of specific 
cytokines. These cytokines regulate VSMC apoptosis in 
culture, but VSMC apoptosis can also induce VSMC pro-
liferation in vivo. VSMC AICP may ameliorate, while AIA 
may amplify the effects of pro-apoptotic stimuli in vessel 
remodeling and disease.
Materials and methods
Isolation and culture of mouse vascular smooth 
muscle cells (VSMCs)
VSMCs were isolated from mouse aorta by digesting with 1 
mg/mL collagenase (Gibco, 17104-019) and 1 U/ml elastase 
(LS006365, Worthington) in serum-free Dulbecco’s Modi-
fied Eagle Medium (DMEM)(D5671, SIGMA), supple-
mented with 2 mM L-glutamine (G7513, SIGMA), 100U/
mL penicillin and 100 µg streptomycin (P0781, SIGMA) for 
10 min at 37 °C. Adventitia was removed and the remain-
ing tissue digested in 2.5 mg/ml collagenase and 2.5 U/ml 
elastase for 2 h with regular trituration. Cells were further 
passaged and maintained in complete DMEM with 10% FCS 
at 37 °C and 5%  CO2 in humidified conditions.
Apoptosis assays
Cultured VSMCs were treated with either 1µM staurosporine 
(Stau)(Sigma, S4400) for 24 h in serum-free DMEM or 10 
ng/ml α-Fas (BD Pharmingen 554255) + 10 nM cyclohex-
imide (CHX)(Sigma, C7698) for 15 h in serum-free DMEM.
Flow cytometry
Apoptosis was assessed by flow cytometry by Annexin-
V (AV) and Propidium iodide (PI). Briefly 1 × 105 cells 
were seeded in 6-well plates and treated with either Stau 
or α-Fas/CHX for 24 and 15 h respectively. Cells were 
trypsinized and stained for AV and PI using the FITC 
Annexin V/Dead Cell Apoptosis Kit (Thermo, V13242) 
according to the manufacturer’s instructions. A BD Accuri 
C6 flow cytometer was used to acquire the data and for 
data analysis. Gating was set according to live unstained 
VSMCs growing in serum-free DMEM (negative control 
for apoptosis).
Fluorescence‑activated cell sorting of apoptotic 
cells
72 × 105 cells were seeded in T75 flasks and treated with 
1µM Stau or 10 ng/ml α-Fas + 10 nM CHX for 24 and 15 
h respectively. Cells were collected and stained for AV and 
PI using the FITC Annexin V/Dead Cell Apoptosis Kit 
(V13242, Thermo).  AV−/−,  AV+/PI− and  AV+/PI+ cell sub-
populations were sorted, singlet discrimination applied, 
and collected in PBS for RNA extraction using a BD FAC-
SAria III sorter. Gating was set according to the following 
controls; Stau-treated cells AV stained only (AV positive 
control), Stau-treated cells PI stained only (PI positive 
control), and live cells unstained (negative control).
Western blotting
Attached apoptotic cells were collected and lysed in 50µ 
l RIPA buffer (Thermo) supplemented with 1X protease 
and phosphatase inhibitors (Merck, 539131, 524625) and 
denatured in 1X NuPAGE LDS containing 1X reducing 
agent (Thermo). 5 µg protein was resolved on pre-cast 
polyacrylamide 4–12% Bolt Bis-Tris Plus gels (Invitrogen) 
and transferred to a polyvinylidene difluoride membrane 
(PVDF) membrane by wet transfer using the Mini Trans-
Blot Module (Biorad). Antibodies used for immunoblot-
ting were from Cell Signaling Technology unless other-
wise stated: p38 (9212S), P-p38 (9211S), JNK (9252), 
P-JNK (4668), Akt (4691S), P-Akt (4060S), cleaved cas-
pase 3 (9661S), STAT3 (9139), P-STAT3 (9145), STAT5 
(D206Y), P-STAT5 (Y694), MK2 (3042), P-MK2 (3041), 
c-Jun (9165), P-c-Jun (3270), β actin (Sigma, A5441-clone 
AC15), Anti-mouse IgG-HRP (7076), Anti-rabbit IgG- 
HRP (7074). Blots were visualized by chemilluminescence 
(GE Healthcare).
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Cell treatments
VSMCs were pre-treated for 1 h with 50µM Z-VAD.FMK 
(R&D Systems FMK001) prior to addition of Stau and 
α-Fas/CHX and incubated for the indicated time points. 
VSMCs were also pre-treated with 10µM SB203580 
(CELL, SM32) and 25µM SP600125 (Sigma, S5567). 
Recombinant proteins were purchased from Peprotech. 
Cells were treated with 100 ng/ml IL-6 (216 − 16) and 
GM-CSF (315-03) or 50 ng/ml of each for combined treat-
ment. Neutralization of IL-6 and GM-CSF in conditioned 
medium was achieved with 0.75 µg/ml of anti-GM-CSF 
(R&D MAB415-SP) and anti-IL-6 (R&D MAB406-SP). 
Inhibition of transcription was performed with 2 µg/ml of 
Actinomycin-D (NovusBio, NB1229).
Preparation of conditioned medium
VSMCs were treated with Stau, α-Fas/CHX or DMSO (vehi-
cle control) in serum-free DMEM for 8 h. Cells were then 
washed twice in PBS and incubated in serum-free DMEM 
for 15 h. Cell supernatants were cleared at 11,000x rpm for 
5 min and concentrated using Vivaspin columns (Generon 
UK) with an exclusion range of 5 kDa. Concentrated con-
ditioned medium was stored at − 80 °C until further use.
Cell cycle analysis
1 × 105 cells were seeded in 6-well plates in DMEM + 10% 
FBS and left to attach overnight. Following 48 h incuba-
tion in serum-free DMEM, cells were further treated for 
24 h with concentrated conditioned medium from Stau, 
α-Fas/CHX or DMSO-treated donor cells supplemented 
with 10µM EdU. Cells were collected by trypsinization 
and stained for EdU, followed by RNase (100 µg/ml) and 
PI (20 µg/ml) treatment as per manufacturer’s instructions 
(Invitrogen, C10632). A BD Accuri C6 flow cytometer was 
used to acquire the data and for data analysis.
Immunohistochemistry
Paraffin-embedded tissues were sectioned at 5 µm intervals. 
Specimens were de-waxed and rehydrated through graded 
ethanols to water and microwaved in 120 mM sodium cit-
rate buffer. Endogenous peroxidase activity was blocked 
with 3% hydrogen peroxide. Sections were then incubated 
in 10% bovine serum albumin in PBS for 1 h at RT and 
then with primary antibodies including MAC3 (BD Bio-
sciences, 553322, 1:500), Ki67 (Abcam, ab16667) overnight 
at 4 °C. HRP-conjugated secondary antibodies were applied 
on the second day and visualized using DAB. Incorpora-
tion of dUTPdigoxigenin (TUNEL assay for apoptosis) was 
detected with an alkaline phosphatase-conjugated antibody 
to digoxigenin (Roche) and development with 5-bromo-4-
chloro-3indoyl-phosphate/p-nitroblue tetrazolium (Vector). 
Quantification was performed as a percentage of positively 
stained cells against total number of cells (3 sections used 
per mouse).
ELISA
Cell culture supernatants were concentrated ~ 10 times on 
columns and subjected to bead-based immunoassays accord-
ing to the manufacturer’s instructions (BD 558301, 558347, 
558296, 558299 560232). Data Acquisition and analysis was 
performed using a BD Accuri C6 flow cytometer and the 
eBioscience FlowCytomixTM Pro software respectively.
Multiplex cytokine array
Cell culture supernatants were concentrated ~ 10 times on 
columns and subjected to a magnetic bead-based multiana-
lyte Luminex assay (R&D systems) according to the manu-
facturer’s instructions. Data acquisition was performed in a 
Luminex Magpix.
qPCR
RNA was extracted from mouse aorta and VSMCs and then 
reverse-transcribed into cDNA using the cDNA synthesis 
kit (BIOLINE, BIO-65053). Expression analysis was per-
formed for IL-6 (forward primer 5′- CTC TGC AAG AGA 
CTT CCA TCCA − 3′ and reverse primer 5′- AGT CTC CTC 
TCC CGG ACT TGT-3′), GM-CSF (forward 5′TGC CTG TCA 
CGT TGA ATG AAG-3′ and reverse 5′- GAA ATT GCC CCG 
TAG ACC CT-3′), TGFβ (forward 5′AAC GGG ATC AGC 
CCC AAA C-3′ and reverse 5′- TCT CTG TGG AGC TGA AGC 
AA-3′), IGFBP-3 (forward 5′-CAC ACC GAG TGA CCG ATT 
CC-3′ and reverse 5′- GTG TCT GTG CTT TGA GAC TCAT-
3′) and IL-18 (forward primer- 5′TCT TGG CCC AGG AAC 
AAT GG-3′ and reverse 5′- ACA GTG AAG TCG GCC AAA 
GT-3′primer sequences). Comparative quantitation was per-
formed using the Rotor-Gene software. For each experimen-
tal sample the relative control sample was used as calibrator 
and all samples were normalized to either Rpl4 (forward 
5′- CGC AAC ATC CCT GGT ATT ACT-3′ and reverse 5′-ACT 
TCC GGA AAG CAC TCT CCG-3′) or 18S (forward 5′- GTA 
ACC CGT TGA ACC CCA TT-3′ and reverse 5′-CCA TCC AAT 
CGG TAG TAG CG-3′).
SM22α‑hDTR mice
All animal studies were undertaken under UK Home Office 
licensing and approved by the Animal Welfare Ethical 
Review Body of the University of Cambridge. C57BL6/J 
SM22α-hDTR mice were generated and genotyped as 
651Apoptosis (2020) 25:648–662 
1 3
previously described [13]. Male and female SM22α-hDTR 
mice and wild type littermates were treated as indicated 
with intraperitoneal doses of 5 ng/g body weight diph-
theria toxin (LIST biological laboratories, 150) diluted in 
0.9% saline and 0.2% BSA.
Carotid ligation expriments
Mice (C57BL6/J SM22α-hDTR /male and female) were 
given a pre-operative injection of buprenorphine (0.1 mg/
kg; subcutaneously) and anaesthetized with 2.5% inhal-
able isofluorane (maintained at 1.5%). The left common 
carotid artery was exposed and ligated just below the 
bifurcation with a 6 − 0 silk suture. Mice were permitted 
to recover for 14d and then sacrificed for collection of 
right and left common carotid arteries. Tissues were fixed 
in 10% neutral-buffered formalin overnight before paraffin 
embedding.
Statistical analysis
Results are presented as mean ± SD unless stated otherwise. 
Two-sample unpaired Student t tests were used for variables 
that were normally distributed and compared between 2 
groups. If the variable was not normally distributed, we con-
ducted a Mann–Whitney test. All statistical analyses were 
performed with GraphPad Prism 7.00 (GraphPad Software 
Inc).
Results
Activation of extrinsic or intrinsic apoptosis 
of VSMCs
To identify pathways and cytokines released when VSMCs 
undergo apoptosis, we treated mouse VSMCs with an ago-
nistic antibody to the death receptor CD95/Fas and 10 nM 
cycloheximide (α-FAS + CHX), a well-characterized acti-
vator of extrinsic apoptosis, or the protein kinase inhibitor 
staurosporine (Stau), a similarly well-established activa-
tor of intrinsic apoptosis, both in 0% serum media. 10 nM 
cycloheximide is well below concentrations that result in 
global protein synthesis inhibition (~ 35µM)[14]. Apoptosis 
was quantified by flow cytometry using propidium iodide 
(PI) and FITC-annexin V (AV). Control VSMCs in 0% FCS 
showed low levels of both apoptosis  (AV+PI−) and second-
ary necrosis  (AV+PI+), while both α-FAS + CHX and stau-
rosporine rapidly induced cell death with apoptosis  (AV+/
PI−) predominating at 15 and 24 h respectively (Fig. 1a-b).
VSMC apoptosis induces synthesis and release 
of IL‑6 and GM‑CSF
To determine the soluble cytokines released during VSMC 
apoptosis, we examined conditioned media of apoptotic 
cells and the adjacent live cells by multiplex cytokine array, 
and quantified relative concentrations of specific cytokines 
by ELISA. The major cytokine released following both 
α-Fas + CHX and staurosporine was IL-6, while GM-CSF 
was also released by α-Fas + CHX (Fig.  1c). To deter-
mine whether synthesis of these cytokines was increased 
by apoptosis, or apoptosis just caused release from pre-
formed stores, VSMCs were incubated with actinomycin D 
(ActD) prior to induction of apoptosis, and IL-6 and GM-
CSF mRNA assayed by qPCR. α-Fas + CHX and stauro-
sporine markedly increased IL-6 mRNA, while α-Fas + CHX 
increased GM-CSF compared with control-treated cells. 
Expression of these cytokine mRNAs was completely 
inhibited by ActD (Fig. 1d), indicating that α-Fas + CHX 
and staurosporine increase IL-6 and GM-CSF in conditioned 
media in part by transcriptional activation.
The cell cultures used above contain cells undergo-
ing apoptosis, secondary necrosis, and adjacent live cells, 
and it is therefore unclear whether IL-6 and GM-CSF are 
released from the dying (apoptotic or secondary necrotic) 
or live cells, or both. For example, both IL-6 and GM-CSF 
are released from VSMCs when stimulated with pro-inflam-
matory cytokines such as IL-1α [15]. We therefore sorted 
VSMCs after α-Fas + CHX or staurosporine treatment using 
annexin V/PI into dying or dead cells  (AV+/PI− and  AV+/
PI+) or live cells  (AV−/PI−), and examined cytokine expres-
sion by qPCR. IL-6 and GM-CSF mRNA expression were 
increased in the population undergoing cell death compared 
with similarly-treated live cells (Fig. 1e).
Apoptosis induces phosphorylation of p38, JNK, 
and Akt
Fas activation induces receptor aggregation, clustering of 
adapter molecules such as FADD (Fas-associated death 
domain), and activation of a number of downstream signal-
ing pathways leading to apoptosis, including activation and 
cleavage of caspases 3, 6, 7 and 8. However, Fas activa-
tion also leads to activation of kinase cascades involving 
mitogen-activated protein kinase kinase kinase 1 (MEKK1), 
Jun amino (N)-terminal kinase kinase 1 (JNKK1), p38 mito-
gen-activated protein kinase (p38MAPK) and Akt/protein 
kinase B (PKB)[16]. The downstream targets of these cas-
cades include Nuclear Factor kappa-light-chain-enhancer 
of activated B cells (NF-κF) and Activator protein 1 (AP1 
sites) on many promoters, including a number of VSMC 
mitogens and apoptosis regulatory proteins (reviewed in [16, 
17]). Similarly, staurosporine induces apoptosis via effects 
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Fig. 1  Fas activation and staurosporine induce apoptosis and secre-
tion of soluble cytokines a Flow cytometric profiles of mouse 
VSMCs treated with α-Fas + 10 nM cycloheximide (CHX) or 1µM 
staurosporine (Stau) for 15 and 24 h respectively stained for annexin 
V (AV) or propidium iodide (PI). b %  AV+/PI− or  AV+/PI+ cells 
after treatment in a. c Cytokine array for secreted cytokines from 
cells treated in a. d Relative mRNA expression of IL-6 or GM-CSF 
mRNA in cells pre-treated with Actinomycin D (ActD) and then 
treated with α-Fas + CHX or Stau, n = 4. e Relative mRNA expression 
in live  (AV−/PI−) or dying/dead  (AV+/PI− or  AV+/PI+) sorted cells 
treated as above Data are means ± SD, n = 3 unless otherwise indi-
cated
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on a wide range of pro-survival and pro-apoptotic protein 
kinases [18], some of which may also promote prolifera-
tion or apoptosis. Thus, pathways leading to apoptosis and 
proliferation may be stimulated simultaneously in the same 
cell or sequentially in adjacent cells by both agents. How-
ever, it is unclear whether synthesis and release of soluble 
cytokines requires caspase cleavage, or is just a by-product 
of simultaneous activation of common upstream pathways.
We therefore examined the time course of phospho-
rylation of p38MAPK, JNK and Akt compared with their 
unphosphorylated forms, and cleavage of caspase 3 after 
treatment with α-Fas + CHX or staurosporine. p38 showed 
some phosphorylation in DMSO-treated cells, but P-p38 
increased significantly after α-Fas + CHX or staurosporine, 
peaking at 8 h. P-JNK also increased after both apoptotic 
stimuli, peaking at 8 h, while P-Akt was increased by 
staurosporine but more variably and not significantly by 
α-Fas + CHX (Fig. 2a)(Supplemental Fig. 1). Cleaved Cas-
pase 3 (CC3) was seen with both α-Fas + CHX and stau-
rosporine, peaking at 8 h and then reduced as cell death 
proceeded (Fig. 2a).
To determine whether caspase cleavage was required for 
activation of p38, JNK or Akt, we incubated cells induced to 
undergo apoptosis with the broad spectrum caspase inhibitor 
ZVAD.fmk and studied P-p38, P-JNK and P-Akt at 8 and 15 
h. Interestingly, ZVAD.fmk had no effect on α-Fas + CHX or 
staurosporine-induced p38 or JNK activation and a variable 
effect on P-Akt (Fig. 2b-c). Furthermore, ZVAD.fmk did not 
reduce α-Fas + CHX or staurosporine-induced induction of 
IL-6 and GM-CSF mRNA expression (Fig. 2d), suggesting 
that Fas and staurosporine-induced transcription of IL-6 and 
GM-CSF does not require caspase activation.
IL‑6 induction requires p38 activity
We next examined whether synthesis of IL-6 and GM-CSF 
during apoptosis requires activation of p38 or JNK, using 
the p38MAPK inhibitor SB203580 or the JNK inhibitor 
SP600125, or both. SB203580 reduced staurosporine-
induced phosphorylation of the p38MAPK target MK2 
while SP600125 reduced staurosporine-induced phosphoryl-
ation of c-Jun (with also some reduction of total c-JUN, most 
likely from autoactivation)(Supplemental Fig. 2), confirming 
the inhibitory effect of these agents. Neither SB203580 nor 
SP600125 inhibited cleaved caspase 3 induced by stauro-
sporine (Supplemental Fig. 2). SB203580 but not SP600125 
inhibited both α-Fas + CHX and staurosporine-induced IL-6 
mRNA expression, and SB203580 reduced α-Fas + CHX-
induced GM-CSF mRNA expression (Fig. 2e-f).
These data show divergence of pathways activated by Fas 
and staurosporine, with different pathways leading to cas-
pase cleavage to those leading to p38, and JNK activation, 
and induction of IL-6 and GM-CSF. In particular, IL-6 and 
GM-CSF induction are dependent upon p38 but not JNK 
activity, while caspase cleavage is not dependent upon either 
p38 or JNK.
VSMC apoptosis induces apoptosis but not cell 
proliferation in adjacent VSMCs in vitro
IL-6 is a mitogen for VSMCs [19, 20], but can also regulate 
apoptosis [21], while GM-CSF has multiple activities on 
VSMCs, including induction of TGFβ which inhibits VSMC 
proliferation, and affects extracellular matrix (ECM) synthe-
sis [22]. Mice deficient in GM-CSF show reduced arterial 
neointima formation after injury, in part by reduced mac-
rophage accumulation and proliferation [23], and VSMCs 
and endothelial cells (ECs) are the major cell expressing 
GM-CSF in early atherogenesis [24, 22]. It is therefore 
unclear whether VSMC apoptosis induces proliferation, 
apoptosis, or neither in adjacent live VSMCs, and whether 
secreted IL-6 or GM-CSF are responsible.
We cultured recipient VSMCs in 0.5% FBS media for 
72 h to induce quiescence. Apoptosis was induced in donor 
VSMCs with α-Fas + CHX or staurosporine, cells washed 
thoroughly after 8 h to remove α-Fas + CHX or stauro-
sporine, fresh 0.5% FBS media replaced, and conditioned 
media collected. Subsequent culture of recipient VSMCs in 
10% serum showed that they retained the ability to rapidly 
enter the cell cycle as determined by EdU incorporation. 
However, the conditioned media from either α-Fas + CHX or 
staurosporine-treated cells failed to induce cell cycle entry, 
even when concentrated 10-fold (Fig. 3a-b). We also exam-
ined whether α-Fas + CHX or staurosporine-conditioned 
media could promote proliferation with a submaximal pro-
liferative stimulus of 5% FBS. 5% FBS induced 1% EdU 
incorporation, but neither α-Fas + CHX nor staurosporine-
conditioned media with 5% FBS increased % EdU incor-
poration above controls (Supplemental Fig. 3). This data 
suggests that the combination of soluble mitogens released 
after Fas or staurosporine-induced apoptosis in culture is 
not sufficient to induce cell proliferation alone, or augment 
proliferation with a submaximal proliferative stimulus of 5% 
FBS.
In contrast, flow cytometric profiles of recipient cells 
showed evidence of a sub-diploid peak that was increased 
by α-Fas + CHX or staurosporine-conditioned media from 
donor cells (Fig.  3b), suggestive of VSMC apoptosis-
induced apoptosis (AIA). IL-6 and GM-CSF can have either 
pro- or anti-apoptotic actions, depending upon concentra-
tion, cell type and stimulus [25–29]. We therefore exam-
ined whether recipient cells showed evidence of intracellular 
signals induced by IL-6 or GM-CSF that regulate prolif-
eration or apoptosis. STAT3 is a major signaling pathway 
that regulates the anti-apoptotic activity of IL-6 [25, 26], 
and STAT5 is also implicated in IL-6 signaling in VSMCs 
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Fig. 2  Apoptosis induces activation of p38, JNK and Akt. a West-
ern blots of mouse VSMCs treated with DMSO (control diluent), 
α-Fas + CHX or Staurosporine for 2–24 h for p38, JNK, Akt, cleaved 
caspase 3 (CC3), or β-actin. b,  c Western blot of VSMCs treated 
with α-Fas + CHX. b or Stau c ± pre-incubation with 50µM ZVAD-
fmk. d qPCR for IL-6 or GM-CSF of cells treated in b,  c. n = 4. e, f 
qPCR for IL-6 or GM-CSF of cells pre-treated with inhibitors to p38 
(SB203580, 10µM) or JNK (SP600125, 25µM) alone or in combi-
nation and apoptosis induced by α-Fas + CHX e or Staurosporine f. 
Data are means ± SD, n = 3
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[30]. Similarly, STAT 3 and 5 regulate GM-CSF signaling 
in multiple cell types [31]. Recipient cells showed activation 
of STAT3 induced by conditioned media from donor cells 
treated with α-Fas + CHX or staurosporine. However, despite 
STAT3 phosphorylation, recipient cells showed increased 
caspase 3 cleavage when incubated in α-Fas + CHX or stau-
rosporine-conditioned media. In contrast, α-Fas + CHX or 
staurosporine-conditioned media did not activate STAT5 in 
A B
C D
E
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recipient cells, a proliferation signal seen after 10% FBS 
treatment (Fig. 3c).
IL‑6 and GM‑CSF in conditioned media are 
pro‑apoptotic
This data suggests that α-Fas + CHX or staurosporine-con-
ditioned media contains a mixture of cytokines that possess 
predominantly pro-apoptotic activity, but are not sufficient 
to induce proliferation from quiescence. Although multiple 
cytokines were released after α-Fas + CHX or staurosporine 
treatment (Fig. 1), we first examined the effects of IL-6 and 
GM-CSF using either recombinant cytokines, or neutralizing 
antibodies on conditioned media-induced apoptosis. Recom-
binant IL-6 induced STAT3 but not STAT 5 phosphoryla-
tion and both IL-6 and GM-CSF could induce apoptosis, 
as indicated by cleavage of caspase 3, with a peak at 15 h 
(IL-6) or 24 h (GM-CSF) (Fig. 3d). Interestingly, IL-6 and 
GM-CSF together potently induced CC3 at 15 h, but the 
CC3 signal was lost by 24 h, most likely due to further CC3 
degradation (Fig. 3d).
Although high concentrations of recombinant IL-6 or 
GM-CSF could induce VSMC apoptosis, we also tested the 
effects of neutralizing IL-6 and GM-CSF in the conditioned 
media. 2.5µ g/ml of a neutralizing antibody to IL-6 or GM-
CSF effectively inhibited activation of STAT3 or STAT5 
respectively as markers of IL-6 and GM-CSF signaling 
(Supplemental Fig. 4). However, the pro-apoptotic effect of 
the conditioned media from α-Fas + CHX or staurosporine-
treated cells could not be inhibited by inhibiting IL-6 or 
GM-CSF. Indeed, neutralizing IL-6 or GM-CSF increased 
CC3 cleavage when cells were treated with conditioned 
media from α-Fas + CHX, and neutralizing IL-6 increased 
CC3 cleavage when cells were treated with conditioned 
media from staurosporine-treated VSMCs (Fig. 3e), sug-
gesting that the levels of IL-6 and GM-CSF in conditioned 
media are anti-apoptotic.
This data suggests that the overall pro-apoptotic effect 
of α-Fas + CHX- or staurosporine-conditioned media 
is likely to be due to relative changes in a large number 
of secreted pro-and anti-apoptotic cytokines. Indeed, 
combinations of pro-inflammatory cytokines including 
IL-1α, TNFα and Interferon-gamma (IFN-γ can induce 
VSMC apoptosis [32, 33] in part by Fas signaling [34]. 
However, IL-1α, TNFα and IFNγ were not detectable in 
α-Fas + CHX or staurosporine-conditioned media. In addi-
tion, there were no consistent changes in the pro-apoptotic 
cytokines IL-18 or insulin-like growth factor binding pro-
tein 3 (IGFBP3), or the anti-apoptotic cytokine TGFβ 
(Supplemental Fig. 5).
VSMC apoptosis induces IL‑6 and GM‑CSF and cell 
proliferation in normal arteries in vivo
Although conditioned media from apoptotic VSMCs 
induced apoptosis rather than cell cycle entry of live 
VSMCs in culture, the effect of VSMC apoptosis on adja-
cent VSMCs in vivo is unclear. For example, VSMCs 
in vivo are in a stable growth-arrested state, unlike cul-
tured VSMCs that have undergone transition to a pheno-
type that shows increased proliferation and susceptibility 
to apoptosis. In addition, VSMC proliferation and apopto-
sis in vivo may be triggered by membrane-bound proteins 
[35] or proteins contained within exosomes [36], which 
are not present in filtered conditioned media. We therefore 
examined transcriptional induction of cytokines and pro-
liferation of VSMCs in the vessel wall following induced 
VSMC apoptosis. SM22α-DTR mice express the human 
diphtheria toxin receptor (DTR) from the minimal SM22α 
promoter (Fig. 4a). Mice are normally resistant to DT, but 
transgenic expression of DTR renders cells susceptible to 
DT-induced apoptosis. DT administration to SM22α-DTR 
mice results in apoptosis of medial or intimal VSMCs in 
normal vessels, after injury, or in atherogenesis [1, 5, 13, 
37]. Furthermore, DT administration to VSMCs derived 
from SM22α-DTR mice causes release of IL-6, MCP-1 
and GM-CSF in culture, and in the presence of hyperlipi-
demia, increases serum levels of TNF-α and IL-6 in vivo 
[37].
We administered DT to SM22α-DTR or wild-type lit-
termate control mice for 48 h. Aortas were collected 24 h 
later and apoptosis examined by TUNEL, IL-6 and GM-
CSF mRNA by qPCR, and cell proliferation by immuno-
histochemistry for Ki67. DT induced apoptosis in SM22α-
DTR but not wild type control mice, with no infiltration of 
 Mac3+ inflammatory cells (Fig. 4b-c). Cell proliferation 
was not detectable in wild type mice after DT administra-
tion, but small numbers of  Ki67+ cells were found 24 h 
after DT administration in the media of SM22α-DTR mice 
(Fig. 4b,d). DT also induced IL-6 mRNA approximately 
3-fold and GM-CSF approximately 20-fold in SM22α-
DTR compared with wild type control mice (Fig. 4e-f).
Fig. 3  Apoptosis of VSMCs induces apoptosis in recipient VSMCs 
.a EdU incorporation of growth-arrested VSMCs after treatment with 
media containing 10% FBS, conditioned media from VSMCs induced 
to undergo apoptosis by α-Fas + CHX or Stau, or DMSO control. b 
Flow cytometric profiles of recipient cells after treatment with condi-
tioned media from control donor cells or apoptotic VSMCs. c West-
ern blot for STAT3, STAT5 and CC3 for recipient cells treated as in 
a. d Western blot for STAT3, STAT5 and CC3 for VSMCs treated 
with 100 ng/ml IL-6 or GM-CSF for 15 or 24 h alone or in combi-
nation (50 ng/ml each). e Western blot for STAT3, STAT5 and CC3 
of recipient cells treated with conditioned media from apoptotic 
VSMCs ± 0.75µ g/ml neutralizing antibodies to IL-6 or GM-CSF. 
N = 3
◂
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Induced VSMC apoptosis augments cell proliferation 
after vessel injury
Vessel injury is associated with massive VSMC apopto-
sis, followed by repopulation of the media to recover its 
cellularity and intima formation through VSMC prolif-
eration and migration. Although VSMC apoptosis can 
induce VSMC proliferation in normal arteries in vivo as 
above, it is unclear whether this local and relatively small 
effect can augment the proliferative actions of mitogens 
A B
C
D
E
Fig. 4  VSMC apoptosis induces VSMC proliferation in vivo. a Sche-
matic of SM22α-DTR transgenic mice and DT administration proto-
col. DT was administered to SM22α-DTR (DTR) or wild-type litter-
mate control (wild type) mice for 48 h and aortas collected at 72 h. 
b TUNEL, or immunohistochemistry for Mac3 or Ki67 in wild-type 
control or SM22α-DTR mice treated with DT for 48 h and sections 
collected at 72 h. Insets show high power views of areas outlined. 
Scale bar = 100µ m. c-d %  TUNEL+ c or  Ki67+ d VSMCs in media 
of mice in b. n = 7–9. e-f qPCR for IL-6 or GM-CSF mRNA in media 
of vessels in b relative to Rpl4. n = 5–6. Data are means ± SD. Scale 
bars = 100µ m
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and release from extracellular matrix restraint that drives 
medial repopulation and intima formation after injury. 
We therefore examined the effect of DT-induced apop-
tosis after left common carotid artery (LCCA) ligation, a 
model of reduced flow-induced neointima formation, and 
in the right common carotid artery (RCCA), which under-
goes compensatory high flow-induced remodeling, both of 
which are accompanied by apoptosis (Fig. 5a). The LCCA 
A
B
C D
Fig. 5  VSMC apoptosis induced after vessel injury augments cell 
proliferation. a Schematic of SM22α-DTR transgenic mice and DT 
administration protocol. The left common carotid artery was ligated 
and DT administered to SM22α-DTR (DTR) or wild-type littermate 
control mice (wild type) on 3 occasions from 1-2w. Carotid arter-
ies were collected at 2w. b-d TUNEL or immunohistochemistry for 
Ki67 b or quantification c-d in left common carotid artery (LCCA) 
or right common carotid artery (RCCA) wild-type control or SM22α-
DTR mice treated with DT. Insets show high power views of areas 
outlined. Scale bar = 100µ m. Data are means ± SD, n = 10
659Apoptosis (2020) 25:648–662 
1 3
was ligated, mice administered DT 3X/week 1w later to 
both groups, and sections analysed at 2w. SM22α-DTR 
mice had increased apoptosis in the RCCA, but not in the 
ligated LCCA at 2w (Fig. 5b,c). In contrast, SM22α-DTR 
mice had increased proliferation in the LCCA but this was 
not seen in the RCCA (Fig. 5b,d).
Discussion
While VSMC apoptosis occurs in normal development and 
a large range of vascular diseases, its effects have been pre-
sumed to be due to loss of VSMC function, in particular 
the structural integrity provided by synthesis or extracellu-
lar matrix proteins. In contrast, the direct effects of VSMC 
A B
C
Fig. 6  Schematic representation of mechanisms in VSMC apoptosis-
induced apoptosis and apoptosis induced compensatory prolifera-
tion. a In vitro stimulation with either α-FAS/CHX or staurosporine 
induces apoptosis via cleavage of caspase 3 and transcription and 
secretion of IL-6 and GM-CSF (α-FAS/CHX) and GM-CSF (α-FAS/
CHX or staurosporine). Conditioned media of apoptotic VSMCs 
induce cleavage of caspase 3 in recipient cells and phosphorylation of 
STAT3, but growth-arrested recipient cells do not enter the cell cycle. 
b Neutralization of IL-6 or GM-CSF in the conditioned medium 
causes cleavage of caspase 3 (α-IL-6 and α-GM-CSF) and reduction 
in p-STAT3 in recipient cells (α-IL6). c In vivo, DT-induces VSMC 
apoptosis in the vessel wall and transcriptional upregulation of IL-6 
or GM-CSF, and proliferation of adjacent VSMCs
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apoptosis, for example release of soluble mediators that can 
have large effects on adjacent live cells, has received less 
attention.
There are a number of novel and important findings in our 
study, summarised in Fig. 6. In particular we show that: (a) 
both extrinsic and intrinsic apoptosis signals induce mRNA 
of both IL-6 and GM-CSF in the dying VSMCs, which are 
then secreted: (b) VSMCs induced to undergo apoptosis 
activate multiple intracellular signaling cascades, including 
phosphorylation of p38, JNK and Akt, as well as activation 
of caspases: (c) caspases are not required for phosphoryla-
tion of p38, JNK and Akt, nor induction of IL-6 and GM-
CSF: (d) p38 but not JNK activation is required for IL-6 and 
GM-CSF induction: (e) conditioned media from apoptotic 
VSMCs does not induce or augment proliferation of adjacent 
live VSMCs from quiescence in culture, but rather induces 
further apoptosis: (f) high concentrations of IL-6 and GM-
CSF can induce VSMC apoptosis, but the concentrations in 
conditioned media from apoptotc VSMCs promote VSMC 
survival, and: (g) VSMC apoptosis induces IL-6 and GM-
CSF in normal vessels in vivo, and increases VSMC prolif-
eration both in normal vessels and after ligation. Apoptotic 
VSMCs are rapidly cleared in normal vessels and TUNEL 
only marks a portion of the apoptotic process; a  TUNEL+ 
% of 2–3% therefore represents significant apoptosis. Sim-
ilarly, VSMCs in normal vessels are in a quiescent (non-
proliferating) state; detection of any proliferating VSMCs in 
otherwise normal vessels therefore represents a significant 
pro-proliferative stimulus.
Apoptosis-induced (compensatory) proliferation (AICP) 
is seen in normal development and tissue homeostasis in a 
wide variety of organisms and tissues (reviewed in [38, 39]). 
Although the precise regulation of AICP is not known, in 
almost all cases developmental AICP requires caspase acti-
vation, and some of the signaling pathways are conserved 
across species. For example, in Drosophila the initiator 
caspase 9 homologue Dronc can activate Drosophila p53 
(Dp53), resulting in secretion of the mitogens Wingless 
(Wg) and Decapentaplegic (Dpp)[38, 39]. JNK signaling 
is implicated in both apoptosis and Wg and Dpp release, 
induced by a variety of stimuli [40].
Although these pathways are established in Drosophila, 
their role in mammalian cell AICP is unclear. Caspases are 
required for cytokine secretion in some systems [41][42] 
and bone morphogenetic protein-2 (BMP2) and Wnts, the 
human homologues of DPP2 and Wg respectively, can regu-
late VSMC proliferation and migration, although not always 
positively [43–45]. In contrast, Fas/FADD activation can 
induce a number of pro-inflammatory genes including MCP-
1, IL-8, tumor-necrosis-factor-stimulated protein (TSG) -6, 
PAI 2, IL-6, GRO1 and IL-1α [46] while caspase inhibition 
could only partially, block upregulation of MCP-1 transcript 
expression, despite complete inhibition of apoptosis [46].
Mammalian cells also possess other AICP pathways not 
defined in other organisms. For example, caspases 3 and 
7 cleave and activate the  Ca2+- independent phospholi-
pase A2 (iPLA2), resulting in release of prostaglandin E2 
(PGE2)[41]. PGE2 promotes AICP in skin and liver [41], 
and can stimulate proliferation of quiescent VSMCs [47]. 
PGE2 can also activate Wnt/β-catenin signalling through 
PI3K/Akt [48]. Previous studies have shown that VSMC 
apoptosis can promote vessel remodeling after carotid 
ligation [5], and diabetic vein graft remodeling is asso-
ciated with a simultaneous increase in proliferation and 
apoptosis of VSMCs [49, 50], although in most cases the 
underlying mechanisms are not clear.
While our studies implicate cytokines such as IL-6 and 
GM-CSF derived from apoptotic VSMCs in AICP, apop-
totic VSMCs also release chemotactic factors (MCP-1 
and M-CSF [5]), and macrophages accumulate after 
VSMC apoptosis in atherosclerosis [1, 13]; thus, local 
macrophage production of VSMC mitogens might also 
promote VSMC AICP. However, we find that intimal or 
medial AICP does not occur after VSMC apoptosis in ath-
erosclerosis either induced acutely or chronically[1, 13], 
implying that VSMCs in atherosclerosis are resistant to 
AICP.
Our study has a number of limitations. First, the con-
ditioned media experiments cannot fully recapitulate the 
exposure of live VSMCs to apoptotic VSMCs in vivo, as 
only small molecular weight soluble cytokines are present, 
excluding the effects of membrane-bound death ligands for 
example, or proteins in exosomes. Second, we cannot iden-
tify a specific cytokine that is responsible for either AICP 
or AIA; rather we predict that the both processes may be 
stimulated simultaneously by the concerted effect of multi-
ple secreted cytokines, with the outcome (death or prolifera-
tion) being regulated by the precise cytokine combination. 
Third, the same cytokine relased from apoptotic cells might 
induce proliferation or apoptosis or protect against apoptosis 
in adjacent cells, dependent upon its local concentration. 
Finally, we did not identify AIA after injury in the carotid 
ligation model using TUNEL, as this does not discriminate 
between DT-induced apoptosis and AIA.
In summary, we show that VSMC apoptosis induces a 
number of cytokines including IL-6 and GM-CSF, through 
pathways that require p38 but not JNK and caspases. VSMC 
apoptosis can induce both apoptosis or cell proliferation in 
adjacent live VSMCs, identifying that both VSMC apopto-
sis-induced apoptosis and apoptosis induced compensatory 
proliferation may occur in vascular development and disease.
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